Process Excellence & Pharma Market | Pharma-IQ, Division of IQPC

7 Unique Challenges Facing the US Generic Pharma Industry

Thu, 17 Jun 2010 04:00:00 GMT

For the US generic drug industry, there are a number of unique challenges, including the

PDCO and Industry Working on a New Relationship

Thu, 10 Jun 2010 04:00:00 GMT

Dr Irja Lutsar Professor of Medical Microbiology, University of Tartu and Member, PDCO

Market Access, New Term for Old Values?

Mon, 07 Jun 2010 04:00:00 GMT

If it ain’t broke don’t fix it! But as Peter Drucker said; “if it

Old Commercial Values No Longer Enough

John Ferguson — Tue, 01 Jun 2010 04:00:00 GMT

As a European, I found it difficult to understand the fervour created by President

Patient Empowerment and Compliance:The Role of Direct to Consumer (DTC) Advertising

James Harris — Wed, 26 May 2010 04:00:00 GMT

It is a given fact that more households are wired to the internet and individuals are

Protecting Your Patent Portfolio and Achieving Optimum Litigation Outcomes: An Interview with Andr� Bourgouin of Ipsen

Fri, 14 May 2010 04:00:00 GMT

The Pharmaceutical & Biotech Patent Litigation Strategies Conference 2010

Pharmacovigilance and Risk Management: Getting to Grips with the Evolving Regulatory Environment

Fri, 04 Jun 2010 04:00:00 GMT

Realising how and why regulatory bodies need to change Understanding developments in

ELNs to Optimise Patent Protection

Wed, 26 May 2010 04:00:00 GMT

Advantages of ELNs for patients. Uses of ELNs for IP matters. Ligitation risks of ELNs.

Understanding the Vital Role of Benefit-Risk Optimisation

Wed, 19 May 2010 04:00:00 GMT

Defining benefit/risk from an FDA and EU perspective. Pinpointing the prerequisites for

Pharmacovigilance & Risk Management

Wed, 19 May 2010 04:00:00 GMT

Describing the scope and objectives of pharmacovigilance and risk management and the

The Evolving Face of Inventive Step in Europe

Thu, 11 Mar 2010 05:00:00 GMT

How different in practice are the approaches to inventive step throughout Europe?

Understanding the Evolving IP Landscape in India and its Effect on Pharmaceutical Patent Litigation

Thu, 11 Mar 2010 05:00:00 GMT

Understanding the IP system in India and how this is changing to come in line with other

Identifying and Overcoming Issues when Planning and Formulating an Effective Patent Litigation Strategy

Thu, 11 Mar 2010 05:00:00 GMT

Deciding what patents to assert (when there is a choice). Deciding where to sue and

The Role of Lifecycle Management in Patent Litigation

Thu, 11 Mar 2010 05:00:00 GMT

• The legality and legitimacy of the "secondary" patents • The

Keynote Presentation: Litigation Trends and Challenges: The International Pharmaceutical and Biotech Industry

Thu, 11 Mar 2010 05:00:00 GMT

• Current trends in innovator vs. generic patent litigation • Key cases that

The European Commissions Pharmaceutical Sector Inquiry

Thu, 11 Mar 2010 05:00:00 GMT

• Discussion of the findings of the pharmaceutical sector inquiry •

The European Commission: Working Towards Consistency in the Patent Courts

Thu, 11 Mar 2010 05:00:00 GMT

• Analysis of the current similarities and differences between different European

Panel Discussion: The Emerging Challenges Linked with Anti-Trust laws in Patent Litigation and Settlements

Thu, 11 Mar 2010 05:00:00 GMT

• Global harmonisation of the viewpoint on anti-trust issues • Anti-trust

Outlining Recent Litigation Practices within the US Judicial Courts

Thu, 11 Mar 2010 05:00:00 GMT

• The US judicial courts view on developing trends concerning pharmaceutical patent

Successfully Litigating within the Dutch Legal System

Thu, 11 Mar 2010 05:00:00 GMT

• Emphasising the key differences in the Dutch legal framework when litigating

Litigation in Practice

Thu, 11 Mar 2010 05:00:00 GMT

• Best practice in preparing for litigation • Specific experience from inside